Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer

Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer

Genetic and epigenetic changes in the mitogen activated protein kinase (MAPK) signaling render urothelial cancer a potential target for tyrosine kinase inhibitor (TKI) treatment. However, clinical trials of several TKIs failed to prove efficacy. In this context, we investigated changes in MAPK signa...

Full description

Bibliographic Details
Main Authors: Judith Knievel, Wolfgang A. Schulz, Annemarie Greife, Christiane Hader, Tobias Lübke, Ingo Schmitz, Peter Albers, Günter Niegisch
Format: Article
Language:English
Published: MDPI AG 2014-11-01
Series:International Journal of Molecular Sciences
Subjects:
tyrosine kinase inhibitor
urothelial cancer
mitogen activated protein kinase (MAPK) signaling
apoptosis
Online Access:http://www.mdpi.com/1422-0067/15/11/20500

Internet

http://www.mdpi.com/1422-0067/15/11/20500

Similar Items